The Science

Experience Driven, Discovery Focused

Focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor.

Nourianz
(Istradefylline, KW-6002)

• First approved in Japan 2013 and then by the FDA November 2019 for Parkinson’s Disease.
• The only approved A2a antagonist.
• Japan ONLY sales in 2019 –> $1B USD

A2a Receptor: A Validated Target

Multiple studies have shown that that A2a Receptor shows the great promise as the key to unlock many different types of diseases.

Proven Players, Focused on True Discovery while Maximizing Capital.

0
+
Years Experience
0
Proven Proprietary Compounds
0
Diseases Affected
0
B
Total Market Value